OPRX - オプティマイザ―Rx （OptimizeRx Corporation） オプティマイザ―RxOPRXのチャート
OPRXの企業情報
| symbol | OPRx |
|---|---|
| 会社名 | OptimizeRx Corp （オプティマイザ―Rx） |
| 分野（sector） | Miscellaneous 雑工業 |
| 産業（industry） | Business Services |
| 業種 | 医薬品 工業（Industrials） |
| 概要 | 事業概要 OptimizeRx Corporation is a technology solutions company. The Company focuses on the healthcare industry. The Company connects patients physicians and pharmaceutical manufacturers through technology. The Company's solutions provide pharmaceutical manufacturers a direct to physician channel for communicating and promoting products. It provides healthcare providers a means to provide sampling and coupons without having to physically store samples on site. The Company's principal products and applications include SampleMD OPTIMIZEHR and OPTIMIZERx.com. SampleMD is a virtual Patient Support Center. OPTIMIZEHR is a consulting practice focused on educating and working with pharmaceutical manufacturers on identifying formulating and implementing new electronic prescribing (eRx) media strategies for promoting their products. OPTIMIZERx.com is a portal to healthcare savings for patients to centrally review and participate in prescription and healthcare savings and support programs. オプティマイザ―Rxは米国の医療ビジネスサ―ビス企業。主に、医療業界におけるテクノロジ―・ソリュ―ションを提供する。同社製品やアプリケ―ションには、医師やスタッフが患者のために医薬品サンプルや割引券を探すことができるシステム、薬局ネットワ―クの検索、臨床メッセ―ジサ―ビスなどを含む。本社所在地はミシガン州ロチェスタ―。 OptimizeRx is a digital health company that provides communications solutions for life science companies, physicians and patients. Connecting over half of healthcare providers in the U.S. and millions of patients through a proprietary network, the OptimizeRx digital health platform helps patients afford and stay on medications. The platform unlocks new patient and physician touchpoints for life science companies along the patient journey, from point-of-care, to retail pharmacy, through mobile patient engagement. |
| 本社所在地 | 400 Water Street Suite 200 Rochester MI 48307 USA |
| 代表者氏名 | Gus D. Halas ガス・D・ハラス |
| 代表者役職名 | Chairman of the Board 取締役会会長 |
| 電話番号 | +1 248-651-6558 |
| 設立年月日 | 31352 |
| 市場名 | NASDAQ Small Cap |
| ipoyear | ―年 |
| 従業員数 | 24人 |
| url | www.optimizerx.com |
| nasdaq_url | https://www.nasdaq.com/symbol/oprx |
| adr_tso | ― |
| EBITDA | EBITDA（百万ドル） -0.57003 |
| 終値（lastsale） | 16.92 |
| 時価総額（marketcap） | 196907278.32 |
| 時価総額 | 時価総額（百万ドル） 196.79090 |
| 売上高 | 売上高（百万ドル） 16.32124 |
| 企業価値(EV) | 企業価値(EV)（百万ドル） 184.78704 |
| 当期純利益 | 当期純利益（百万ドル） -0.76852 |
| 決算概要 | 決算概要 BRIEF: For the six months ended 30 June 2018 OptimizeRx Corporation revenues increased 84% to $9.2M. Net income totaled $91K vs. loss of $1.2M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Net Income reflects Consultants decrease of 63% to $64K (expense) Depreciation and amortization decrease of 50% to $109K (expense). |
OPRXのテクニカル分析
OPRXのニュース
OptimizeRx Has A Good Growth Path Ahead (NASDAQ:OPRX) 2023/04/03 21:16:43 Seeking Alpha
OptimizeRx is an exciting opportunity for investors who want to gain exposure to a growing market, which is the pharma ad spending.
OptimizeRx launches $15M stock buyback plan 2023/03/14 11:46:44 Seeking Alpha
OptimizeRx (OPRX) has announced a share repurchase program to buyback up to $15M of its outstanding common stock.The announcement follows the health technology company''s fourth…
OptimizeRx Authorizes $15 Million Share Repurchase Program 2023/03/14 11:30:00 GlobeNewswire
ROCHESTER, Mich., March 14, 2023 (GLOBE NEWSWIRE) -- OptimizeRx Corp . (the “Company”) (Nasdaq: OPRX), a leading provider of point-of-care technology solutions helping patients start and stay on therapy, announced today that its Board of Directors has unanimously authorized a share repurchase program, under which OptimizeRx may repurchase up to $15 million of its outstanding common stock.
OptimizeRx bags contract with Hub services company for better patient access 2023/03/09 13:10:22 Seeking Alpha
Point-of-care technology solutions provider, OptimizeRx (OPRX) announced a multi-million-dollar, three-year agreement with a leading Hub services company.It will leverage…
OptimizeRx Corporation (OPRX) Q4 2022 Earnings Call Transcript 2023/03/09 03:23:03 Seeking Alpha
OptimizeRx Corporation (NASDAQ:NASDAQ:OPRX) Q4 2022 Earnings Conference Call March 8, 2023 4:30 PM ETCompany ParticipantsWill Febbo - CEOEd Stelmakh - CFO and COOSteve Silvestro - Chief…
Melinta Therapeutics & OptimizeRx Announce 2022 Innovate4Outcomes Event 2022/11/30 14:43:00 Business Wire
Melinta Therapeutics, LLC (Melinta), a commercial-stage company providing innovative patient care therapies for acute and life-threatening illnesses,
Here’s Why Artisan Partners Exited its Position in OptimizeRx Corporation (OPRX) 2022/11/14 15:44:03 Insider Monkey
Artisan Partners, an investment management company, released its “Artisan Small Cap Fund” third quarter 2022 investor letter. A copy of the same can be downloaded here. In the third quarter, its Investor Class fund ARTSX returned 3.23%, Advisor Class fund APDSX posted a return of 3.27%, and Institutional Class fund APHSX returned 3.27%, compared to a […]
Was anything positive for OptimizeRx Corporation (OPRX) stock last session? 2022/11/10 13:08:00 US Post News
As of Wednesday, OptimizeRx Corporation’s (NASDAQ:OPRX) stock closed at $17.77, up from $14.52 the previous day. While OptimizeRx Corporation has overperformed by 22.38%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, OPRX fell by -79.30%, with highs and lows ranging from $93.67 to $13.33, whereas the […]
Meta Platforms, Hilton Grand Vacations, D.R. Horton, And Some Other Big Stocks Moving Higher On Wednesday 2022/11/09 15:54:21 Benzinga
U.S. stocks traded lower, with the Nasdaq dropping more than 100 points on Wednesday. Here are some big stocks recording gains in today’s session. Merrimack Pharmaceuticals, Inc. (NASDAQ: MACK ) shares climbed 219% to $12.80 after partner Ipsen reported Onivyde met its primary and key secondary endpoint. Merrimack is eligible for up to $450 million in milestone payments for the pancreatic cancer treatment. Outset Medical, Inc. (NASDAQ: OM ) surged 36.1% to $15.61 after the company reported better-than-expected Q3 results. OptimizeRx Corporation (NASDAQ: OPRX ) climbed 28% to $18.58 following better-than-expected Q3 results. Health Catalyst, Inc. (NASDAQ: HCAT ) rose 23% to $7.95 after the company reported better-than-expected Q3 EPS and sales results. The company also issued FY22 sales guidance above analyst estimates. Vivint Smart Home, Inc. (NYSE: VVNT ) gained 21.4% to $8.50 after the company posted upbeat quarterly sales and raised FY22 revenue guidance. LiveRamp Holdings, Inc. (NYSE: RAMP ) rose 21% to $18.91 after the company reported better-than-expected Q2 results and issued strong guidance.
OptimizeRx Corporation (OPRX) Q3 2022 Earnings Call Transcript 2022/11/09 05:56:10 Seeking Alpha
OptimizeRx Corporation (NASDAQ:NASDAQ:OPRX) Q3 2022 Earnings Conference Call November 8, 2022 16:30 ET Company Participants Will Febbo - Chief Executive Officer Ed Stelmakh - Chief…
OptimizeRx extends reach with Cooler Screens Partnership 2022/07/26 12:16:18 Seeking Alpha
OptimizeRx (OPRX) has announced a partnership with Cooler Screens, a media and merchandising platform that brings the best aspects of in-store digital advertising into the…
With -3.8% Distance From Low, Is OptimizeRx Corporation (NASDAQ:OPRX) Poised For More Gains? 2022/07/23 16:00:00 Marketing Sentinel
In last trading session, OptimizeRx Corporation (NASDAQ:OPRX) saw 0.7 million shares changing hands with its beta currently measuring 0.86. Company’s recent per share price level of $20.55 trading at -$3.81 or -15.64% at ring of the bell on the day assigns it a market valuation of $355.10M. That closing price of OPRX’s stock is at … With -3.8% Distance From Low, Is OptimizeRx Corporation (NASDAQ:OPRX) Poised For More Gains? Read More »
SVB Leerink Sees ''Cheaper Way'' To Pharma Digital Marketing With This Stock 2022/07/15 19:10:54 Benzinga
SVB Leerink initiated coverage on OptimizeRx Corporation (NASDAQ: OPRX ) with a buy rating and a price target of $38, implying an upside of 36%. The analysts say OptimizeRx is the largest EHR-embedded messaging network and enjoys a solid financial profile of 30%+ top-line growth and mid-teens adjusted EBITDA margins. Despite this, the valuation is cheap. The stock currently trades at an ~2.5 turn discount to pharma digital … Full story available on Benzinga.com